KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Share-based Compensation (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Share-based Compensation for 10 consecutive years, with $268000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Share-based Compensation rose 111.68% to $268000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $300000.0, a 50.25% decrease, with the full-year FY2024 number at $830000.0, up 37.65% from a year prior.
  • Share-based Compensation was $268000.0 for Q4 2024 at Palvella Therapeutics, up from -$331000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q3 2020 to a low of -$2.3 million in Q4 2023.
  • A 5-year average of $780500.0 and a median of $1.1 million in 2020 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: plummeted 341.83% in 2023, then skyrocketed 111.68% in 2024.
  • Palvella Therapeutics' Share-based Compensation stood at $1.2 million in 2020, then grew by 12.44% to $1.3 million in 2021, then decreased by 28.11% to $949000.0 in 2022, then tumbled by 341.83% to -$2.3 million in 2023, then surged by 111.68% to $268000.0 in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Share-based Compensation are $268000.0 (Q4 2024), -$331000.0 (Q3 2024), and $217000.0 (Q2 2024).